As part of the university's commitment to economic development and outreach, CTL hosts a variety of events to create connections between the Cornell campuses, industry members, entrepreneurs, and investors.
Building a Successful Startup Mini Startup Boot Camp will feature two panels of experts who will share their advice on developing a successful start-up business. Specifically, they will discuss topics like how to identify your market and evaluate competitors, what key traits make a business attractive to investors and partners, legal aspects to consider and other tips for entrepreneurial success.
A networking reception will follow the panels where hors d’oeuvres and drinks will be served.
Open to: The Weill Cornell community and all those interested in technology-based entrepreneurship. Please register for this event here.
Structuring Your Startup for Long-Term Success
Moderator: Paul Hughes, Wiggin and Dana
Business Considerations for Starting a Life Sciences Venture
Moderator: Lily Wound, Wiggin and Dana
- Bill Burkoth, Pfizer Venture Investments
- Jim Farrington, Wiggin and Dana
- Alan Paau, CCTEC
- Mike Sherman, Elm Street Ventures
Paul Hughes is the former Chair of Wiggin and Dana's Corporate Practice Department and also practices in the Health Care Department. He is experienced with the representation and operation of both mature and emerging growth companies in a variety of industries including energy and utilities, information technology, clean technology, telecommunications, biotechnology, health care services, manufacturing and outsourcing.
Paul regularly represents clients in the areas of debt and equity financings, mergers, acquisitions, divestitures, joint ventures, strategic alliances, and corporate governance.
Paul has served as Vice President and General Counsel of a venture capital-backed pediatric health care services company, and its pediatric clinical trials network. He was active in all aspects of business development, corporate strategy and operations and was responsible for all of the companies' legal affairs, including equity and debt financing transactions, mergers and acquisitions, strategic alliances, licensing, real estate leasing, and contract negotiations.
Chambers USA lists Paul as one of the leading corporate/M&A lawyers in Connecticut. He is also listed in Best Lawyers in the area of Private Equity Funds.
Paul is admitted to practice in Connecticut. He earned his B.A. from the University of Connecticut and was awarded his J.D. with honors from the University of Connecticut School of Law, where he served as an Articles Editor of the Connecticut Law Review. Following graduation, he held the position of law clerk to Justice Fleming L. Norcott, Jr. of the Connecticut Supreme Court.
Lily Wound is a Counsel in Wiggin and Dana's Corporate Department and Biotechnology and Life Sciences Practice Group. Ms. Wound has counseled clients in a variety of industries, including life sciences, media, Internet, software and healthcare information and technology. Her practice focuses on the representation of clients in connection with a wide range of corporate transactions, including mergers and acquisitions, corporate finance, joint ventures and strategic alliance. She also has significant experience in structuring and negotiating intellectual property licenses and other complex business relationships.
Before joining Wiggin and Dana, Ms. Wound was Counsel at Kaye Scholer LLP where she worked extensively with pharmaceutical, biotechnology, vaccine and other life sciences clients. Ms. Wound was also in-house counsel for Hearst Corporation, where she advised on all aspects of Hearst's businesses relating to traditional media, new media, digital media and healthcare information and technology. Her responsibilities at Hearst included leading all complex transactions in the newspapers division and serving as general counsel for an evidence-based medical information and technology company. Ms. Wound began her career at the international law firm of Coudert Brothers LLP.
Ms. Wound received her J.D. from The George Washington University Law School. She received her Master of Public Health from Boston University School of Public Health and her B.A., cum laude, in the Biochemical Sciences from Harvard University where she completed her senior honors thesis in genetics.
Bill is currently a Senior Director of Pfizer Ventures, the venture capital arm of Pfizer Inc. Since joining Pfizer in early 2004, Bill has played an instrumental role in numerous new venture capital investments, including Avid Radiopharmaceuticals (acquired by Eli Lilly), Clovis Oncology (Nasdaq: CLVS), Evolution Benefits (acquired by Genstar Capital), and HandyLab (acquired by Becton Dickinson). Bill currently serves on the board of directors of Biodesy, DVS Sciences and Novocure, and as a board observer of HD Biosciences (Shanghai, China), Epic Sciences, M2S, and Nodality. He is also a member of the investment committee of the Investment Fund for Health in Africa (IFHA) and the Burrill Brazil Fund. Prior to joining Pfizer, Bill worked in Business Development at Galileo Pharmaceuticals and at IntraBiotics Pharmaceuticals. Prior to his roles in business development, Bill was an analyst at Bay City Capital. Mr. Burkoth received a BA in chemistry from Whitman College and an MBA from Columbia Business School.
Jim Farrington is a partner in Wiggin and Dana's Corporate Practice Department and chairs the firm's Biotechnology and Life Sciences Practice Group.
Jim's practice includes commercial business transactions, especially acquisitions, joint ventures, licensing and other technology transfer transactions. A large portion of his clients are based in Europe. Jim has significant experience in biotech and other pharmaceutical and medical device transactions, including international license and distribution agreements, strategic alliances, venture capital investments, and research and development agreements.
After graduating with a chemical engineering degree from the University of Notre Dame, Jim worked as an engineering and product manager for nearly nine years in the air pollution control field. Before joining Wiggin and Dana, Jim was a partner in the New York office of Mannheimer Swartling, Sweden's largest law firm. Jim and his family lived in Stockholm for two years when he was leading the legal team for a $1 billion divestment of a global pharmaceutical business.
Jim graduated with a B.Ch.E. from the University of Notre Dame and received his law degree with high honors from Quinnipiac University School of Law.
Scott Kaufman is a partner in the Wiggin and Dana's Corporate Department. He focuses on mergers and acquisitions for private and public companies, private equity and strategic transactions, including venture capital financings, and public and private securities offerings. Scott is based in the New York office.
Many of his clients are early stage digital media and technology companies. Scott's clients also include publicly traded and privately held companies, venture capital and hedge funds, investor groups, executives and entrepreneurs. These clients are in a number of industries, including Internet, biotech, telecommunications, retail and software.
Scott advises domestic and foreign clients on SEC and Sarbanes-Oxley compliance and corporate governance matters, serves as outside general counsel to a number of his clients and has significant experience advising special committees in connection with related-party transactions as well as boards and audit committees in restatement issues and internal investigations. He also has worked on a range of transactions with Israeli hi-tech companies, entrepreneurs and venture capital firms.
He co-authored the chapter titled Forming a Board: Issues for Directors and Founders in the Practicing Law Institute publication Advising High-Technology Companies.
Scott received his J.D. with honors from Duke University School of Law and a B.A. with distinction from The University of Michigan. He is admitted to practice in New York.
Jonathan Kfoury joined L.E.K. Consulting in 2006, and since that time has led a broad range of corporate and commercial strategy assessments for emerging and leading biopharmaceutical clients. Mr. Kfoury also advises clients on portfolio strategy, R&D and commercialization planning for in-line and pipeline assets, and business development / partnering strategy.
Select recent client engagements include: Developing an R&D and partnering strategy for an innovative start-up biopharmaceutical company focused on novel therapies for CNS-related disease and leading a comprehensive analysis of future environmental disruptors that could impact a top Big Pharma's long-term strategic plan, and key opportunities to exploit / integrate.
Prior to joining L.E.K., Mr. Kfoury was a business development executive for Acusphere Inc. and Purdue Pharma L.P. Earlier in his career, Mr. Kfoury was manager of global clinical development for Cubist Pharmaceuticals' antibiotic Cubicin®, the most successful IV antibiotic launched in U.S. history.
In addition to global management training at INSEAD, Mr. Kfoury earned an S.M. in Health Policy & Management from Harvard University, and graduated from Trinity College with a Bachelor of Science degree in Neuroscience.
Dr. Paau is responsible for the strategic management of all technologies and intellectual property that arise from the research activities at Cornell University - both at the Weill Medical College in New York City and at the general campus in Ithaca.
Prior to joining Cornell in January 2007, Dr. Paau for nine years was Director and Assistant Vice Chancellor for Technology Transfer & Intellectual Property Services at the University of California, San Diego (San Diego, CA). From 1994 to 1998, he was Executive Director of the Iowa State University Research Foundation, Inc. and Director of Intellectual Property & Technology Transfer at Iowa State University (Ames, IA). Until 1994, he was Associate Director of the Biotechnology Center at the Ohio State University (Columbus, OH) with responsibilities in research, teaching, research administration, technology management, and industry liaison.
Dr. Paau held faculty appointments while at Iowa State University in the departments of Preventive Medicine, Immunology & Microbiology, and Genetics & Zoology, and at the Ohio State University in the departments of Microbiology, and Plant Pathology.
Before returning to the academic environment in 1992, Dr. Paau held various research and management positions of increasing responsibilities in the Cetus Corporation and the W.R. Grace & Co. organizations for 12 years and led the development of two commercial products.
Dr. Paau holds a Ph.D. degree in Biological Sciences and a Master of Business Administration degree. He also attended the Drake University School of Law. Dr. Paau is the inventor to 8 US patents with foreign equivalents and has contributed thirty peer-reviewed research articles to scientific journals and six invited reviews and chapters to technical books.
Dr. Paau speaks often at professional seminars and international conferences and currently serves on the Boards of Directors of The BayHelix Group, Vivo Development, Inc., NanoTecNexus, and the Cornell Research Foundation, Inc. where he also serves as its president. Dr. Paau currently serves as an advisor to the Big Red Consultants, the China Medical City, Startup World Cup – New York Region, Chinese Association for Science and Business, and NYC BIO. As a director of intellectual property, a licensing executive, and a Certified Licensing Professional, he has supervised the execution of over 1600 technology transactions and the formation of over 140 startup companies using licensed technologies. Recognitions of his contributions to the technology management and community development efforts include the 2006 San Diego Bio-Pharma Award (SABPA), the 2005 Vision Award (SDCA), listing in 2004 "People to Watch" (San Diego Union-Tribute), the "Power List 2002" (T-Sector Magazine), and the 2002 Community Champion Award (UCSD). Previously, he also received a NATO Molecular Biology Fellowship Award (EMBO), and an Outstanding Graduate Student Presentation Award (ASPP).
Kevin Rakin was most recently the President of Regenerative Medicine at Shire plc, a leading specialty biopharmaceutical company. Prior to joining Shire, Mr. Rakin served as the Chairman and CEO of Advanced BioHealing (ABH) from 2007 until its acquisition by Shire for $750 million, in June 2011. Before this, he served at the interim CEO of ABH and executive-in-residence at Canaan Partners. Previously, he was a co-Founder, President & Chief Executive Officer of Genaissance Pharmaceuticals, Inc., a publicly held pharmacogenomics company, until its merger with Clinical Data, Inc. in October 2005.
He currently serves on the executive committee for Connecticut United for Research Excellence (CURE), Connecticut¹s bioscience cluster and as a board member of CyVek, Inc, Cheetah Medical Inc., Histogenics Corp. and Tela Bio, Inc. He has previously served as a board member for Ipsogen SA, Vion Pharmaceuticals, Inc., OMRIX Biopharmaceuticals, Inc, and Clinical Data, Inc. Rakin holds an M.B.A. from Columbia University and received B.Com and B.Com (Hons) degrees from the University of Cape Town, South Africa.
Michael I. Sherman
Dr. Sherman carried out and/or supervised basic and applied research for almost twenty years at Hoffmann-La Roche, managing drug discovery in three therapeutic areas. Since 1990, he has co-founded and served as the initial President of seven biotechnology companies, including PharmaGenics (sold to Genzyme); Prostagen (sold to Cytogen); Molecular Staging (sold to Qiagen); Protometrix (sold to Invitrogen) and Affomix (sold to Illumina). Five of the companies Dr. Sherman has co-founded have been based at least in part on research conducted at Yale University. In addition to extensive experience in fundraising for his companies, Dr. Sherman has established numerous corporate and academic relationships and helped to structure and negotiate a number of mergers and acquisitions. Dr. Sherman has also served as consultant, advisor or director for a number of therapeutic, diagnostic, reagent, device, software, and investment companies, for academic and other non-profit institutions and for government agencies. Dr. Sherman is a Partner at Elm Street Ventures, a New Haven-based Venture Capital firm focusing on start-up companies. Following his undergraduate work at McGill University, Dr. Sherman received his PhD in molecular biology from the State University of New York and carried out postdoctoral studies at the University of Oxford.